(19)
(11) EP 4 816 352 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24898711.7

(22) Date of filing: 27.11.2024
(51) International Patent Classification (IPC): 
C07D 209/02(2006.01)
A61K 31/165(2006.01)
A61P 25/00(2006.01)
C07D 217/00(2006.01)
A61K 31/40(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 25/00; C07D 401/14; C07D 401/04; C07D 471/04; C07D 413/14; C07D 417/14; C07D 409/14; C07D 413/04; C07D 487/04; C07D 519/00
(86) International application number:
PCT/US2024/057646
(87) International publication number:
WO 2025/117662 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 29.11.2023 US 202363604173 P
14.02.2024 US 202463553526 P

(71) Applicant: Actio Biosciences, Inc.
San Diego, CA 92130 (US)

(72) Inventors:
  • STOCK, Nicholas Simon
    Encinitas, California 92024 (US)
  • GOVEK, Steven
    San Diego, California 92129 (US)
  • KATANA, Ashley
    Fairview Park, OH 44126 (US)

(74) Representative: Casalonga 
Casalonga & Partners Bayerstraße 71/73
80335 München
80335 München (DE)

   


(54) HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS